Becton, Dickinson and Company (BDX) Q3 FY26 earnings call

BD delivered a strong Q3 FY26, exceeding revenue and EPS expectations, driven by broad-based commercial momentum and double-digit growth in key platforms like biologic drug delivery and advanced patient monitoring. The company raised its full-year revenue outlook to the high end of its low single-digit range and increased adjusted EPS guidance, reflecting confidence in its 'new BD' strategy and operational execution. While navigating headwinds from Alaris, vaccines, and China, management emphasized the positive mix benefits and productivity gains from BD excellence, with preliminary FY27 outlo